BioArctic will participate at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. The conference is focusing on mechanisms, clinical strategies, and promising treatments of neurodegenerative diseases and will take place on March 29 to April 2, 2017.
At the conference, the company will present two posters entitled:
- Intramuscular injection of sonicated α-synuclein fibrils induces α-synuclein pathology and motor deficits in h[A30P]αSYN transgenic mice
- Increased levels of toxic Abeta protofibrils in Alzheimer’s disease brain support the importance of Abeta protofibrils in Alzheimer’s disease pathogenesis.
With patients in mind, BioArctic strives to improve the quality in life for patients with Alzheimer’s and Parkinson’s diseases. BioArctic’s proprietary technologies, dedicated personnel, innovative collaborations with research groups at universities and partnerships with the pharmaceutical industry have made it possible to develop new immunotherapeutic approaches to neurodegenerative diseases. The company is focused on developing disease modifying treatment based on the company’s antibodies
“We are looking forward to present our innovative data, to follow progression in the field and to interact with our global network,” says Gunilla Osswald, CEO at BioArctic AB.
For more information, please contact:
Gunilla Osswald, CEO, BioArctic AB
Christer Möller, CSO, BioArctic AB
Telephone +46 (0)8 695 6930